AVITA Medical Files 8-K on Material Agreement, Financials; Details Pending

TL;DR

**AVITA Medical filed an 8-K about a new agreement and financials, but no details yet.**

AI Summary

AVITA Medical, Inc. filed an 8-K on January 10, 2024, indicating an "Entry into a Material Definitive Agreement" and disclosing "Results of Operations and Financial Condition." While the filing confirms these events, it does not provide specific details about the agreement or the financial results. This matters to investors because without the specifics, it's impossible to assess the impact of these potentially significant events on the company's future performance or stock value.

Why It Matters

This filing signals important corporate actions and financial updates are coming, but the lack of specific details means investors are currently in the dark about their potential impact.

Risk Assessment

Risk Level: medium — The filing indicates significant events without providing details, creating uncertainty and potential for future volatility once information is released.

Analyst Insight

A smart investor would monitor AVITA Medical's subsequent filings and announcements closely for the specific details of the material agreement and financial results, as these will be crucial for evaluating the company's future prospects.

Key Players & Entities

• AVITA Medical, Inc. (company) — the registrant filing the 8-K
• January 10, 2024 (date) — date of earliest event reported and filing date
• 001-39059 (other) — Commission File Number for AVITA Medical, Inc.
• Delaware (other) — State of Incorporation for AVITA Medical, Inc.

Forward-Looking Statements

• AVITA Medical will release specific details regarding the 'Material Definitive Agreement' and 'Results of Operations and Financial Condition' in a subsequent filing or announcement. (AVITA Medical, Inc.) — high confidence, target: Q1 2024
• The stock price of AVITA Medical may experience volatility once the specific details of the material agreement and financial results are disclosed. (AVITA Medical, Inc.) — medium confidence, target: Q1 2024

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share RCEL The Nasdaq Stock Mar

Filing Documents

• rcel-20240110.htm (8-K) — 50KB
• rcel-ex99_1.htm (EX-99.1) — 20KB
• rcel-ex99_2.htm (EX-99.2) — 20KB
• img262816717_0.jpg (GRAPHIC) — 20KB
• img262816717_1.jpg (GRAPHIC) — 20KB
• img263740238_0.jpg (GRAPHIC) — 20KB
• img263740238_1.jpg (GRAPHIC) — 20KB
• 0000950170-24-003621.txt ( ) — 325KB
• rcel-20240110.xsd (EX-101.SCH) — 25KB
• rcel-20240110_htm.xml (XML) — 5KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. Distribution Agreement On January 10, 2024, AVITA Medical Americas LLC (“AVITA Americas”), a wholly-owned subsidiary of AVITA Medical, Inc., (the “Company”) entered into an exclusive multi-year distribution agreement (“Agreement”) with Stedical Scientific, Inc. (“Stedical Scientific”) to commercialize PermeaDerm Biosynthetic Wound Matrix in the United States. PermeaDerm is cleared by the Food and Drug Administration as a transparent matrix for use in the treatment of a variety of wound types until healing is achieved. Under the terms of the agreement, AVITA Americas will hold the exclusive rights to market, sell, and distribute PermeaDerm products, including any future enhancements or modifications, within the United States. The initial term is for five years, with the option to automatically renew for an additional term of five years, contingent upon meeting certain minimums. AVITA Americas also agrees to purchase and maintain minimum quantities of the product to meet the needs of customers and provide monthly and quarterly reporting to Stedical Scientific regarding sales. Purchases of the product from Stedical Scientific do not have the right of return, and AVITA Americas holds title and risk of loss. In accordance with the Agreement, AVITA Americas' gross margin from the sale of PermeaDerm will be 50% of the average sales price. Minimum Purchase Requirements AVITA Americas’ purchases from Stedical Scientific are subject to minimum requirements. Stedical Scientific may terminate the Agreement upon one year notice if AVITA Americas (1) fails to reach its minimum purchase obligation for two consecutive years and (2) also fails to cure such shortfall with a cash payment or sufficient purchase of products. Right of First Negotiation If at any time during the term of the Agreement, Stedical Scientific receives a written offer from a third-p

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On January 10, 2024, the Company issued a press release announcing certain preliminary unaudited results for the fourth quarter and full-year ended December 31, 2023. A copy of the press release is attached hereto as Exhibit 99.1. The information under this Item 2.02 and Exhibit 99.1 is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be deemed incorporated by reference into any filing made under the Securities Act of 1933 except as expressly set forth by specific reference in such filing.

01. Regulation FD

Item 7.01. Regulation FD. On January 10, 2024, the Company issued a press release announcing the entry into the Agreement. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.2. The information under Item 7.01 and Exhibit 99.2 is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be deemed incorporated by reference into any filing made under the Securities Act of 1933 except as expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits 99.1 AVITA Medical Announces Preliminary 2023 Financial Highlights, Provides 2024 Financial Guidance and Business Update 99.2 AVITA Medical Announces Exclusive Distribution Agreement with Stedical Scientific 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AVITA Medical, Inc Date: January 10, 2024 By: /s/ Donna Shiroma Donna Shiroma General Counsel

View Full Filing

View this 8-K filing on SEC EDGAR